Merck KGaA Doesn’t Rule Out Pursuing Lung-Cancer Vaccine

Merck KGaA hasn’t ruled out pursuing its therapeutic cancer vaccine L-BLP25 after a trial showed the treatment prolonged the lives of a group of advanced lung cancer patients by 50 percent compared with placebo.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.